NCT02083250 - Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 6, 2014

Primary Completion Date

November 12, 2021

Study Completion Date

November 12, 2021

Conditions

Acute Lymphoblastic Leukemia in RemissionAcute Myeloid Leukemia in RemissionAllogeneic Hematopoietic Stem Cell Transplantation RecipientMyelodysplastic SyndromePreviously Treated Myelodysplastic SyndromeRecurrent Acute Lymphoblastic LeukemiaRecurrent Acute Myeloid Leukemia

Interventions

PROCEDURE

Allogeneic Bone Marrow Transplantation

Undergo allogeneic peripheral blood stem cell or bone marrow transplant

PROCEDURE

Allogeneic Hematopoietic Stem Cell Transplantation

Undergo allogeneic peripheral blood stem cell or bone marrow transplant

BIOLOGICAL

Anti-Thymocyte Globulin

Given IV

DRUG

Busulfan

Given IV

DRUG

Clofarabine

Given IV

DRUG

Fludarabine Phosphate

Given IV

PROCEDURE

Peripheral Blood Stem Cell Transplantation

Undergo allogeneic peripheral blood stem cell or bone marrow transplant

OTHER

Pharmacological Study

Correlative studies

DRUG

Vorinostat

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER